Leerink Partnrs Has Positive Outlook of Lantheus Q1 Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) - Research analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for Lantheus in a report issued on Thursday, May 1st. Leerink Partnrs analyst R. Ruiz now anticipates that the medical equipment provider will earn $1.44 per share for the quarter, up from their prior estimate of $1.29. The consensus estimate for Lantheus' current full-year earnings is $6.01 per share. Leerink Partnrs also issued estimates for Lantheus' Q2 2025 earnings at $1.52 EPS, Q3 2025 earnings at $1.55 EPS, Q4 2025 earnings at $1.59 EPS, FY2025 earnings at $6.10 EPS and FY2026 earnings at $7.18 EPS.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.69 earnings per share.

Other analysts have also recently issued research reports about the stock. B. Riley reduced their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $134.33.

Lantheus Trading Down 23.2 %

LNTH traded down $24.31 during trading on Monday, reaching $80.53. 7,205,620 shares of the company's stock were exchanged, compared to its average volume of 938,764. Lantheus has a one year low of $74.28 and a one year high of $126.89. The firm has a fifty day moving average price of $100.46 and a two-hundred day moving average price of $94.89. The stock has a market capitalization of $5.51 billion, a PE ratio of 13.40 and a beta of 0.23.

Insider Activity at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 63,109 shares of company stock valued at $6,016,046. 2.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. World Investment Advisors LLC bought a new position in shares of Lantheus in the third quarter valued at approximately $60,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus in the 3rd quarter worth about $25,000. Tidal Investments LLC grew its position in Lantheus by 25.2% during the third quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider's stock valued at $1,934,000 after buying an additional 3,547 shares during the period. GAMMA Investing LLC grew its position in Lantheus by 118.0% during the fourth quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider's stock valued at $91,000 after buying an additional 551 shares during the period. Finally, Everence Capital Management Inc. purchased a new stake in Lantheus during the fourth quarter worth about $210,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.